Ascend
IGF-1 LR3
Growth signaling, extended.
Order Inclusions
What it does for you
- /01Studied for prolonged IGF-1 receptor signalling in laboratory models
- /02Examined in cellular growth and differentiation research
- /03Used in research on protein-synthesis signalling pathways
- /04Presented as a fixed 1mg research vial
Batch Documentation
No current batch documents are published for this product.
Confirm current documentationIGF-1 LR3 Research Notes
What is IGF-1 LR3?
Long R3 IGF-1, commonly written as IGF-1 LR3, is an engineered analogue of insulin-like growth factor 1. It contains an N-terminal extension and an arginine substitution at position three of the IGF-1 sequence.
These structural changes were developed as research tools to reduce affinity for insulin-like growth factor binding proteins while retaining activity at the IGF-1 receptor. This allows researchers to study IGF signalling under conditions that differ from native IGF-1.
Published IGF-1 LR3 research is predominantly preclinical, including cell and animal models. ASCEND is an investigational research product and is not approved for medical use.
What the research shows
The evidence base for IGF-1 LR3 is not comparable with large human clinical programmes. The most relevant findings concern its design and use as a laboratory analogue:
Analogue design: The Long R3 structure combines an N-terminal extension with replacement of glutamate by arginine at position three of the IGF-1 sequence.
Binding-protein affinity: Early analogue studies found markedly reduced interaction with IGF binding proteins compared with native IGF-1.
Cell-model potency: In cell lines that secrete IGF binding proteins, Long R3 IGF-1 showed greater apparent biological potency than native IGF-1, supporting its use as a research reagent.
Evidence limits: Cell and animal findings cannot establish safety, efficacy, or dosing for people, and should not be presented as clinical outcomes.
Reference: Francis G.L. et al. (1992). Journal of Molecular Endocrinology, 8(3), 213–223. PMID: 1378742.
Ordering IGF-1 LR3 in Bali
ASCEND contains a 1mg research vial. Confirm the exact item, current availability, complete Bali delivery address, route, daily cutoff, and timing with BioPepTech before ordering.
Common Questions
Q: How is IGF-1 LR3 different from native IGF-1?
IGF-1 LR3 has an N-terminal extension and an arginine substitution at position three. These changes reduce binding-protein affinity and alter its behaviour as a laboratory research analogue.
Q: Is IGF-1 LR3 the same as somatropin HGH?
No. Somatropin activates growth-hormone receptors and can influence IGF-1 production. IGF-1 LR3 is a modified IGF-1 analogue studied for direct IGF-1 receptor signalling.
Q: What does the 1mg vial label mean?
It identifies the total labelled compound content in the sealed vial. It is not a dosing recommendation or administration guide.
Q: How should ASCEND be stored in Bali?
Keep the sealed vial refrigerated at 2–8°C and protected from heat and direct light. Follow product and batch-specific handling instructions after reconstitution.